Table 3 Prognostic value of immune cell types in TCGA TNBC (multivariate).
Model | OS HR (95% CI) pvalue (continuous) | OS HR (95% CI) pvalue (high vs. low) (rows 1-5 and 6-10: 0.25 * sd) (rows 11-13: cluster analysis) | DFS HR (95% CI) pvalue (continuous) | DFS HR (95% CI) pvalue (high vs. low) (rows 1-5 and 6-10: 0.25 * sd) (rows 11-13: cluster analysis) |
|---|---|---|---|---|
CD8 T cells | 0.000067 (2.2e−08 to 0.20) 0.019 | 0.19 (0.039–0.87) 0.033 | 0.067 (7.2e−04 to 6.22) 0.24 | 0.51 (0.21–1.22) 0.13 |
Pathologic stage | 10.15 (3.51 to 29.35) 1.9e−05 | 9.25 (2.71–31.61) 0.00039 | 5.90 (2.73 to 12.77) 6.6e−06 | 4.95 (1.99–12.36) 0.00060 |
Age at pathologic diagnosis | 0.91 (0.86 to 0.98) 0.0077 | 0.91 (0.85–0.98) 0.0084 | 0.95 (0.90 to 1.01) 0.083 | 0.94 (0.89–1.01) 0.070 |
Menopause status | 2.55 (0.82 to 7.93) 0.11 | 3.16 (0.88–11.32) 0.077 | 1.74 (0.61 to 4.97) 0.30 | 1.77 (0.58–5.37) 0.31 |
Ethnicity | 1.69 (0.50 to 5.71) 0.40 | 2.16 (0.51–9.20) 0.30 | 1.66 (0.58 to 4.73) 0.34 | 2.25 (0.71–7.18) 0.17 |
CD4 memory activated T cells | 0.000047 (3.7e−12 to 579.37) 0.23 | 0.70 (0.21–2.34) 0.56 | 0.0000054 (4.27e−12 to 6.88) 0.091 | 0.61 (0.23–1.61) 0.32 |
Pathologic stage | 5.98 (2.39 to 14.98) 0.00013 | 7.63 (2.36–24.72) 0.00070 | 5.21 (2.45 to 11.11) 0.000019 | 7.49 (2.72–20.65) 0.00010 |
Age at pathologic diagnosis | 0.92 (0.86 to 0.99) 0.017 | 0.92 (0.85–1.00) 0.050 | 0.94 (0.89 to 1.00) 0.052 | 0.94 (0.88–1.00) 0.064 |
Menopause status | 2.46 (0.70 to 8.64) 0.16 | 1.33 (0.37–4.71) 0.66 | 2.01 (0.67 to 6.02) 0.21 | 1.24 (0.41–3.74) 0.71 |
Ethnicity | 2.34 (0.64 to 8.60) 0.20 | 1.93 (0.45–8.29) 0.38 | 1.53 (0.54 to 4.32) 0.42 | 1.31 (0.43–4.02) 0.64 |
CD8/CD4 (cluster analysis) | 0.21 (0.045–0.97) 0.045 | 0.41 (0.16–1.07) 0.068 | ||
Pathologic stage | 6.78 (2.31–19.96) 0.00051 | 4.46 (1.84–10.80) 0.00094 | ||
Age at pathologic diagnosis | 0.95 (0.90–1.00) 0.053 | 0.97 (0.92–1.01) 0.14 |
